Neurocrine Biosciences Inc (NBIX)

NASDAQ
98.24
+0.84(+0.86%)
After Hours
98.24
0.00(0.00%)
- Real-time Data
  • Volume:
    832,682
  • Day's Range:
    95.81 - 99.05
  • 52 wk Range:
    71.88 - 108.01

NBIX Overview

Prev. Close
97.4
Day's Range
95.81-99.05
Revenue
1.21B
Open
98.4
52 wk Range
71.88-108.01
EPS
0.73
Volume
832,682
Market Cap
9.37B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
750,327
P/E Ratio
133.65
Beta
0.64
1-Year Change
-2.33%
Shares Outstanding
95,576,662
Next Earnings Date
Aug 02, 2022
What is your sentiment on Neurocrine?
or
Market is currently closed. Voting is open during market hours.

Neurocrine Biosciences Inc Analysis

Neurocrine Biosciences Inc Company Profile

Neurocrine Biosciences Inc Company Profile

Employees
900

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyBuy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
    0
    • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
      0
      • today 100 :)
        0
        • Crazy but great dip to buy.
          0
      • Time to own NBIX. Last $131.56.
        0
        • $NBIX PDUFA for the Parkinson drug, Opicapone, is due on 4/26 My gut feeling tells me that it will be a GO!
          1